A life without asthma
The global health impact of Peptinnovate’s first in class immune regulating medicines promises to be extremely significant. Our goal is to benefit patients to experience periods of remission without medication and for payers and healthcare providers to benefit from reduced hospitalisations and other costs.
Unique Selling Points
PIN201104 offers 3 key clinical unique selling propositions over current treatments as well as a margin opportunity based on the current pricing models:
- Immune Regulating Therapy for Asthma: Peptinnovate’s medicines in development have the potential to modify the course of immuno-inflammatory disease, including disease remission with short dosing regimen with long lasting effects
- Broad Spectrum of activity: PIN201104 is effective at reducing recruitment of the key inflammatory cell types implicated in asthma, specifically eosinophils (allergic asthma) and neutrophils (non-allergic asthma and COPD)
- Enhanced safety profile: By evolution and design PIN201104 shows an excellent safety profile, which is especially important in a vulnerable patient population